29.37MMarket Cap-610P/E (TTM)
1.8300High1.6800Low118.93KVolume1.7200Open1.7200Pre Close207.61KTurnover0.77%Turnover RatioLossP/E (Static)16.14MShares5.650052wk High-2.58P/B28.29MFloat Cap1.430052wk Low--Dividend TTM15.54MShs Float2687.5000Historical High--Div YieldTTM8.72%Amplitude1.4300Historical Low1.7450Avg Price1Lot Size
Palatin Technologies Stock Forum
Medical Technology Company Presents Dry Eye Disease Clinical Trial Results at The ASCRS
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
$Palatin Technologies(PTN.US)$ this company is huge opportunity it has massive funding with 6B USD it’s go to the top 100% sure.
my advice is buy
the $Palatin Technologies(PTN.US)$ will go to the point because it has 6B USD funding
now buy this is moment
Hope you took a ride
Clinical Breakthrough: Palatin Technologies Unveils Positive Phase 3 Results for PL9643 in Dry Eye Disease Treatment, Paving the Way for FDA Approval Talks
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple seco...
Update
Benzinga· 2 mins ago
loading...
loading...
Palatin In A Glance
No comment yet